These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 20005957)

  • 21. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
    Jana NR; Zemskov EA; Wang Gh ; Nukina N
    Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low levels of mutant ubiquitin are degraded by the proteasome in vivo.
    van Tijn P; Verhage MC; Hobo B; van Leeuwen FW; Fischer DF
    J Neurosci Res; 2010 Aug; 88(11):2325-37. PubMed ID: 20336771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteasomal dysfunction in aging and Huntington disease.
    Li XJ; Li S
    Neurobiol Dis; 2011 Jul; 43(1):4-8. PubMed ID: 21145396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frameshift proteins in Alzheimer's disease and in other conformational disorders: time for the ubiquitin-proteasome system.
    van Leeuwen FW; Hol EM; Fischer DF
    J Alzheimers Dis; 2006; 9(3 Suppl):319-25. PubMed ID: 16914870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Dose-Dependent Pleiotropic Effects of the UBB
    Banasiak K; Szulc NA; Pokrzywa W
    Front Mol Biosci; 2021; 8():650730. PubMed ID: 33842548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. +1 Proteins and aging.
    van Leeuwen FW; Gerez L; Benne R; Hol EM
    Int J Biochem Cell Biol; 2002 Nov; 34(11):1502-5. PubMed ID: 12200043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modest proteasomal inhibition by aberrant ubiquitin exacerbates aggregate formation in a Huntington disease mouse model.
    de Pril R; Hobo B; van Tijn P; Roos RA; van Leeuwen FW; Fischer DF
    Mol Cell Neurosci; 2010 Mar; 43(3):281-6. PubMed ID: 20005957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective degeneration in YAC mouse models of Huntington disease.
    Van Raamsdonk JM; Warby SC; Hayden MR
    Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Huntington disease: new insights on the role of huntingtin cleavage.
    Wellington CL; Leavitt BR; Hayden MR
    J Neural Transm Suppl; 2000; (58):1-17. PubMed ID: 11128600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testing the possible inhibition of proteasome by direct interaction with ubiquitylated and aggregated huntingtin.
    Valera AG; Díaz-Hernández M; Hernández F; Lucas JJ
    Brain Res Bull; 2007 Apr; 72(2-3):121-3. PubMed ID: 17352935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is the ubiquitin-proteasome system impaired in Huntington's disease?
    Ortega Z; Díaz-Hernández M; Lucas JJ
    Cell Mol Life Sci; 2007 Sep; 64(17):2245-57. PubMed ID: 17604996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Huntington's disease model mouse and neuronal cell death].
    Ishiguro H; Sawada H; Nishii K; Yamada K; Nagatsu T
    No To Shinkei; 2001 Sep; 53(9):829-37. PubMed ID: 11596477
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.